Advantage Partners hopes to find a buyer for convenience store chain am/pm Japan by September, after a proposed sale to Lawson Inc. fell apart. The firm also plans to list soft drinks maker Pokka Corp. next year.

American Capital has agreed to sell People Media, operator of targeted dating websites, to Match.com, a unit of IAC/InterActive Corp. The all-cash deal is valued at $80 million. People Media had $11.6 million in 2008 EBITDA.

ArcLight Capital Partners said that it will oppose the $2 billion takeover of Venture Production by Centrica. Also in opposition is Venture co-founder Larry Kinch. ArcLight and Kinch hold a combined 12.8 percent stake in Venture.

Arsenal Capital Partners has sold Sermatech, a Pottstown, Penn.-based maker of protective coatings and processes used on industrial and aviation gas turbines, to Praxair Surface Technologies, a subsidiary of Praxair Inc. No financial terms were disclosed. Sermatech generated $116 million worth of revenue in 2008, and has 625 employees.

Black Canyon Capital has sponsored a recapitalization of JDC Healthcare, a Dallas-based dental practice management company. No financial terms were disclosed for the recap, which was done in partnership with company management.

Boeing Co. is in talks to buy certain operations of supplier Vought Aircraft Industries, as first reported by Flightblogger.com. Vought is a portfolio company of The Carlyle Group.

OpenGate Capital has sold Global Star Solutions to company management, for an undisclosed amount. Global Star Solutions is a Canadian provider of supplier of network infrastructure products, which OpenGate originally bought from UTStarcom.

PAI Partners will take a €256 million ($357.9 million) hit on its investment in troubled French roofing group Monier after a lender consortium won control of the company.

Synovis Life Technologies Inc. has agreed to acquire the assets of Pegasus Biologics Inc., an Irvine, Calif.-based developer of bioimplants for soft-tissue repair and wound care for diabetic ulcers. The deal is valued at $12.1 million. Pegasus Biologics ceased operations earlier this year, after being unable to secure new financing. It had previously raised $32 million over three funding rounds, from Onset Ventures, Affinity Capital Management, Three Arch Partners and Frazier Healthcare Ventures.